Antares Pharma to Report Second Quarter 2017 Financial and Operating Results and Host Webcast and Conference Call
August 01 2017 - 7:00AM
Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release
its second quarter 2017 financial results and recent operating
progress before the market opens on Tuesday, August 8, 2017.
Management will host a webcast and conference call at 8:30 a.m. ET
(Eastern Time) on August 8, 2017 to discuss the results.
Interested parties may participate in the
conference call by dialing 1-866-548-4713 (U.S.) or 1-323-794-2093
(international) and entering access code 9657985. We
encourage interested parties to dial into the conference call at
least 10 minutes prior to the scheduled start time. A replay
of the conference call will be available from 11:30 a.m. ET on
Tuesday, August 8, 2017, through 11:30 a.m. ET on Thursday,
September 7, 2017 by dialing 1-888-203-1112 (U.S.) or
1-719-457-0820 (international), and entering the access code
9657985. An audio webcast and archive of the conference call
will also be available under the investor information section of
the Antares Website at www.antarespharma.com.
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP®
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. The
Company’s product Sumatriptan Injection USP, is approved in the
U.S. for the acute treatment of migraine and cluster headache and
is distributed by Teva Pharmaceutical Industries, Ltd.
(Teva). Antares Pharma is also developing
XYOSTED™ for testosterone replacement therapy and has filed a New
Drug Application with the Food and Drug Administration. The
Company's technology platforms include VIBEX® disposable auto
injectors, disposable multi-use pen injectors and reusable
needle-free injectors. Antares Pharma has license, development and
supply agreements with Teva that include VIBEX® epinephrine,
exenatide multi-dose pen, and teriparatide multi-dose pen.
Our reusable needle-free injector for use with human growth hormone
(hGH) is sold worldwide by Ferring B.V. The Company is also
working with AMAG Pharmaceuticals on a subcutaneous method for
administering Makena, a progesterone product indicated for use in
lowering the risk of pre-term birth. For more information,
visit www.antarespharma.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: U.S. Food and Drug
Administration (“FDA”) approval of the XYOSTED NDA and future
market acceptance and revenue for XYOSTED; the outcome of the
pending patent litigation between Teva Pharmaceutical Industries,
Ltd. (Teva) and Eli Lilly and Company regarding the Teriparatide
multi-dose pen; FDA action with respect to Teva’s Abbreviated New
Drug Application (“ANDA”) for the Teriparatide multi-dose pen and
the timing and approval, if any, by the FDA of the same; FDA
approval of the VIBEX® epinephrine pen ANDA and the timing and
therapeutic equivalence rating thereof, and any future revenue pre
or post FDA approval; Teva’s ability to successfully commercialize
VIBEX® Sumatriptan Injection USP and the amount of revenue from the
same; FDA action with respect to Teva’s ANDA filed for the
Exenatide pen and future revenue from the same; continued growth of
prescriptions and sales of OTREXUP®; the timing and results
of the development project with AMAG Pharmaceuticals for an auto
injector for Makena; the timing and results of research projects,
clinical trials, and product candidates in development;
actions by the FDA or other regulatory agencies with the respect to
the Company’s products or product candidates of its partners;
continued growth in product, development, licensing and royalty
revenue; the Company’s ability to obtain financial and other
resources for its research, development, clinical, and commercial
activities and other statements regarding matters that are not
historical facts, and involve predictions. These statements involve
known and unknown risks, uncertainties and other factors that may
cause actual results, performance, achievements or prospects to be
materially different from any future results, performance,
achievements or prospects expressed in or implied by such
forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2016, and in
the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking
statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this press
release, except as required by law.
Contacts:
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Oct 2023 to Oct 2024